Recent News

• 04.16.2025 - INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
• 04.14.2025 - INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
• 04.01.2025 - INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
• 03.27.2025 - INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
• 03.24.2025 - INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

Recent Filings

• 04.14.2025 - 8-K Current report
• 04.14.2025 - EX-99.1 EX-99.1
• 04.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.09.2025 - 8-K Current report
• 04.09.2025 - EX-99.1 EX-99.1
• 04.01.2025 - EX-99.1 EX-99.1
• 04.01.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]